In this webcast, our tax specialists will discuss key areas impacting healthcare providers including academic medical centers, universities, and other tax-exempt organizations.
After a record second quarter, the pharmaceutical and life sciences (PLS) industry continued to demonstrate a healthy deal value and volume in the third quarter. Closed deal volume increased from the prior quarter to 59 from 46 transactions, with deal value decreasing to $67.6 billion from $72.2 billion. Announced and pending transactions continued to shine at $118.9 billion in deal value and 110 transactions.
US venture capital funding for the life sciences sector, which includes biotechnology and medical devices, increased 60% by value, but declined 4% by volume, on a year-over-year basis during the third quarter of 2015.
This report identifies leading practices healthcare boards are using to prepare for new challenges, and the type of governance infrastructure that may be needed in the new health economy.
In this quarterly webcast focusing on emerging accounting developments affecting not-for-profit organizations, we discuss FASB standard setting developments that have occurred since our July webcast, recent developments related to the not-for-profit financial statement project, and more.
In this webcast replay, we discuss how innovative providers are embedding analytics across their risk and compliance programs to enable earlier escalation of potential issues, enhancing the feedback loop through the use of visualization techniques, and achieving continuous monitoring of key risks.
In this webcast, our tax specialists will discuss key issues surrounding Unrelated Business Taxable Income (UBTI) for tax-exempt hospitals, universities and other nonprofits and what organizations should be focused on to ensure their organization is mindful of the potential UBTI impact of certain activities.
In this edition of Rx Marketplace Quarterly, we discuss the most recent quarter's industry IPOs, venture capital funding, and M&A activity. On the regulatory front, we provide you with information on recent personnel changes at the SEC, proposed audit committee disclosure requirements, and a proposed clawback rule. Additionally, we feature a section on managed monitoring and testing services, and how our Risk Assurance team can assist companies in this area.
This paper contains an overview of monetization strategies, their perceived risks and benefits, and how PwC can help companies evaluate factors associated with this approach.
US venture capital funding for the life sciences sector, which includes biotechnology and medical devices, increased 21% by value, but declined 2% by volume, on a year-over-year basis during the second quarter of 2015. Venture capitalists invested $3.1 billion in 201 life sciences deals in the second quarter of 2015, compared with $2.6 billion in 205 deals during the same quarter of 2014. Also, significant to note, Biotech investment was the highest since the start of the MoneyTree data series in 1995.